Grand Hopital de Charleroi asbl

Charleroi, Hainaut 6000

0 studies enrolling now · 3 studies all time

What they study most

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC), Locally Recurrent Breast Cancer, Metastatic Breast Cancer, Metastatic gpNMB Over-expressing Triple Negative Breast Cancer

Studies at this site

• TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations — Running, not enrolling
• Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer — Stopped early
• Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer — Completed